Lipid-Lowering Agents: Targets Beyond PCSK9 (vol 124, pg 386, 2019)

被引：0
|
作者：
Hegele
机构：
来源：
CIRCULATION RESEARCH | 2020年 / 127卷 / 10期
关键词：
D O I：
10.1161/RES.0000000000000444
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E251 / E251
页数：1
相关论文
共 50 条
  • [1] Lipid-Lowering Agents Targets Beyond PCSK9
    Hegele, Robert A.
    Tsimikas, Sotirios
    [J]. CIRCULATION RESEARCH, 2019, 124 (03) : 386 - 404
  • [2] Lipid-lowering drugs and PCSK9
    Millan Nunez-Cortes, Jesus
    Mostaza Prieto, Jose M.
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 9 - 13
  • [3] Statins and PCSK9 inhibitors: A new lipid-lowering therapy
    Gallego-Colon, Enrique
    Daum, Aner
    Yosefy, Chaim
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 878
  • [4] PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
    Cainzos-Achirica, Miguel
    Martin, Seth S.
    Cornell, John E.
    Murow, Cynthia D.
    Guallar, Eliseo
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) : 64 - 65
  • [5] PCSK9 antibodies: A new class of lipid-lowering drugs
    Gouni-Berthold, Ioanna
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 21 - 27
  • [6] Genetics for the Identification of Lipid Targets Beyond PCSK9
    Wang, Linda R.
    Hegele, Robert A.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2017, 33 (03) : 334 - 342
  • [7] Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy
    Lavecchia, Antonio
    Cerchia, Carmen
    [J]. FUTURE MEDICINAL CHEMISTRY, 2019, 11 (05) : 423 - 441
  • [8] PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy
    Denegri, Andrea
    Petrova-Slater, Iveta
    Pasotti, Elena
    Rossi, Maria Grazia
    Pedrazzini, Giovanni Battista
    Moccetti, Tiziano
    Moccetti, Marco
    [J]. JOURNAL OF CARDIOVASCULAR MEDICINE, 2016, 17 (04) : 237 - 244
  • [9] The association between lipid-lowering drugs and circulating concentration of PCSK9
    Reiner, Zeljko
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (09) : 928 - 929
  • [10] Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
    Ouyang, Mingqi
    Li, Chenyu
    Hu, Die
    Peng, Daoquan
    Yu, Bilian
    [J]. CLINICA CHIMICA ACTA, 2023, 538 : 113 - 123
12345